{"id":"https://openalex.org/W2363852307","doi":null,"title":"Comparison of the efficacy of gefitinib and erlotinib as a second line treatment for advanced non-small cell lung cancer","display_name":"Comparison of the efficacy of gefitinib and erlotinib as a second line treatment for advanced non-small cell lung cancer","publication_year":2012,"publication_date":"2012-01-01","ids":{"openalex":"https://openalex.org/W2363852307","mag":"2363852307"},"language":"en","primary_location":{"id":"mag:2363852307","doi":null,"is_oa":false,"landing_page_url":"https://en.cnki.com.cn/Article_en/CJFDTOTAL-SYYZ201220053.htm","pdf_url":null,"source":{"id":"https://openalex.org/S2764666221","display_name":"Shiyong yixue zazhi","issn_l":"1006-5725","issn":["1006-5725"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/P4361729662","host_organization_name":"Medical Information of Guangdong Province","host_organization_lineage":["https://openalex.org/P4361729662"],"host_organization_lineage_names":["Medical Information of Guangdong Province"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Shiyong yixue zazhi","raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5067560223","display_name":"Zhang De-fan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Zhang De-fan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5067560223"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":{"value":0.37483764,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":96},"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/gefitinib","display_name":"gefitinib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":1.0},{"id":"https://openalex.org/keywords/advanced-non-small-cell-lung-cancer","display_name":"advanced non-small cell lung cancer","score":0.8920000195503235},{"id":"https://openalex.org/keywords/second-line-treatment","display_name":"second-line therapy","score":0.8069999814033508},{"id":"https://openalex.org/keywords/egfr-tyrosine-kinase-inhibitors","display_name":"EGFR tyrosine kinase inhibitors","score":0.9679999947547913},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8230000138282776},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9679999947547913},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.8370000123977661},{"id":"https://openalex.org/keywords/histological-tumor-type","display_name":"tumor histological type","score":0.7139999866485596},{"id":"https://openalex.org/keywords/squamous-cell-carcinoma","display_name":"squamous cell carcinoma","score":0.9670000076293945}],"concepts":[{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.9850647449493408},{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.9804926514625549},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7937856912612915},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.7766915559768677},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6930288076400757},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6405686736106873},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.6131162047386169},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.5529720783233643},{"id":"https://openalex.org/C2909325608","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib Hydrochloride","level":5,"score":0.5448293089866638},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.4803922772407532},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4284300208091736},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.322818398475647}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2363852307","doi":null,"is_oa":false,"landing_page_url":"https://en.cnki.com.cn/Article_en/CJFDTOTAL-SYYZ201220053.htm","pdf_url":null,"source":{"id":"https://openalex.org/S2764666221","display_name":"Shiyong yixue zazhi","issn_l":"1006-5725","issn":["1006-5725"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/P4361729662","host_organization_name":"Medical Information of Guangdong Province","host_organization_lineage":["https://openalex.org/P4361729662"],"host_organization_lineage_names":["Medical Information of Guangdong Province"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Shiyong yixue zazhi","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2418692205","https://openalex.org/W2040181388","https://openalex.org/W2802963011","https://openalex.org/W1993718411","https://openalex.org/W2070444157","https://openalex.org/W2348666640","https://openalex.org/W2357703221","https://openalex.org/W2152171507","https://openalex.org/W2591352563","https://openalex.org/W2887628796"],"abstract_inverted_index":{"Objective":[0],"To":[1],"compare":[2],"the":[3,36,40,47,67,83,109,113,132,145],"efficacy":[4],"and":[5,16,55,75,142],"safety":[6],"of":[7,66,88,103],"epidermal":[8],"growth":[9],"factor":[10],"receptor":[11],"tyrosine":[12],"kinase":[13],"inhibitor":[14],"gefitinib":[15,99,129],"erlotinib":[17,92,122,143],"alone":[18],"as":[19],"a":[20],"second":[21],"line":[22],"treatment":[23,49,140],"for":[24,50],"patients":[25,42,117,135],"with":[26,118,136],"advanced":[27,133],"non-small":[28],"cell":[29],"lung":[30],"cancer(NSCLC)":[31],"who":[32,43],"were":[33,44,70,78,105],"failed":[34,45],"in":[35,46,91,98,116,121,128],"first-line":[37,48,138],"chemotherapy.Methods":[38],"Among":[39],"83":[41],"NSCLC,41":[51],"received":[52,57],"gefitinib(gefitinib":[53],"group)":[54],"42":[56],"erlotinib(erlotinib)":[58],"therapy.The":[59],"efficacy,progression-free":[60],"survival":[61,63,114],"time(PFS),median":[62],"time(MST),and":[64],"toxicity":[65],"two":[68,84,110],"groups":[69],"compared.Results":[71],"The":[72],"median":[73,76],"PFS":[74],"OS":[77],"not":[79],"significantly":[80,106],"different":[81,107],"between":[82,108],"groups(P":[85,111],"0.05).The":[86],"rate":[87],"adverse":[89],"events":[90],"group":[93,123],"was":[94,124],"higher":[95],"than":[96,126],"that":[97,127],"group.The":[100],"histological":[101],"types":[102],"tumor":[104],"0.05),and":[112],"time":[115],"squamous":[119],"carcinoma":[120],"longer":[125],"group.Conclusion":[130],"In":[131],"NSCLC":[134],"standard":[137],"chemotherapy":[139],"failure,gefitinib":[141],"had":[144],"similar":[146],"overall":[147],"efficacy.":[148]},"counts_by_year":[{"year":2017,"cited_by_count":2}],"updated_date":"2025-10-10T17:16:08.811792","created_date":"2016-06-24T00:00:00"}